Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Liver symbols : Nvo save search
Liver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight
Published: 2023-07-12 (Crawled : 21:00) - prnewswire.com
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: 1.7%
H: 0.01%
C: -0.32%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.08%
H: 0.46%
C: -1.26%
MDGL | $222.18 -2.7% -2.8% 270K
|
Health Technology
|
| O: 0.41%
H: 3.34%
C: 1.43%
LPCN | $5.47 2.82% 2.74% 21K
|
Health Technology
|
| O: 0.11%
H: 2.15%
C: 1.02%
GALT | $3.36 -0.59% -0.6% 150K
|
Health Technology
|
| O: 0.64%
H: 7.01%
C: 5.1%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 0.69%
H: 1.02%
C: 0.29%
AKRO | $20.535 -4.93% -5.19% 760K
|
Health Technology
|
| O: 0.78%
H: 1.1%
C: -0.15%
cirrhosis liver growth market
iECURE Raises $65 Million to Advance In Vivo Gene Editing Programs for the Treatment of Rare Pediatric Liver Diseases
Published: 2022-11-30 (Crawled : 14:00) - biospace.com/
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: 2.1%
H: 0.56%
C: 0.56%
DTIL | $10.77 -6.43% -6.87% 71K
|
Health Technology
|
| O: 1.54%
H: 4.55%
C: 3.79%
treatment rare liver
Liver Fibrosis Market to Surge at a CAGR of 15.9% by 2032 | DelveInsight
Published: 2022-09-05 (Crawled : 16:00) - prnewswire.com
SGMT | $3.97 -2.46% -2.52% 340K
|
Health Technology
| Email alert
Add to watchlist
ETNB | $8.9 -2.84% -2.92% 680K
|
Health Technology
| Email alert
Add to watchlist
MDGL | $222.18 -2.7% -2.8% 270K
|
Health Technology
| Email alert
Add to watchlist
LPCN | $5.47 2.82% 2.74% 21K
|
Health Technology
| Email alert
Add to watchlist
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
| Email alert
Add to watchlist
GALT | $3.36 -0.59% -0.6% 150K
|
Health Technology
| Email alert
Add to watchlist
fibrosis liver market
Insulin Delivery Devices Market to Hit $39,371.8 Million Revenue by 2030, says P&S Intelligence
Published: 2022-03-18 (Crawled : 07:00) - prnewswire.com
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: 0.66%
H: 0.0%
C: 0.0%
MDT | $79.19 0.14% 0.0% 6.1M
|
Health Technology
|
| O: 2.46%
H: 0.6%
C: 0.41%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.12%
H: 1.93%
C: 0.63%
BDX | $233.15 0.41% 0.15% 890K
|
Health Technology
|
| O: 0.68%
H: 0.55%
C: 0.24%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.62%
H: 1.07%
C: 0.89%
PODD | $164.71 -0.93% -0.94% 590K
|
Health Technology
|
| O: -0.35%
H: 5.54%
C: 5.11%
device liver intel insulin
At 9.7% CAGR, Insulin Delivery Devices Market Size to hit USD 33.05 Billion in 2028, Says Brandessence Market Research
Published: 2022-01-03 (Crawled : 12:00) - prnewswire.com
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: -2.14%
H: 0.0%
C: 0.0%
MDT | $79.19 0.14% 0.0% 6.1M
|
Health Technology
|
| O: -0.14%
H: 0.0%
C: 0.0%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.78%
H: 0.0%
C: 0.0%
BDX | $233.15 0.41% 0.15% 890K
|
Health Technology
|
| O: -0.43%
H: 0.0%
C: 0.0%
PODD | $164.71 -0.93% -0.94% 590K
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
ce mark device research liver insulin
Global $19 Billion Home-Use Insulin Delivery Devices Markets, 2015-2020 & 2021-2030
Published: 2021-12-20 (Crawled : 19:00) - prnewswire.com
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: 1.2%
H: 1.62%
C: 1.37%
MDT | $79.19 0.14% 0.0% 6.1M
|
Health Technology
|
| O: 0.45%
H: 2.78%
C: 1.68%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.2%
H: 0.74%
C: 0.33%
BDX | $233.15 0.41% 0.15% 890K
|
Health Technology
|
| O: 0.57%
H: 0.63%
C: -0.8%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.76%
H: 0.67%
C: 0.45%
PODD | $164.71 -0.93% -0.94% 590K
|
Health Technology
|
| O: 0.29%
H: 3.22%
C: 3.08%
device liver insulin
Transdermal Drug Delivery Market is Growing at a CAGR of 9.8% during the Study Period from 2021 to 2026, Asserts DelveInsight
Published: 2021-12-14 (Crawled : 17:00) - prnewswire.com
TRUMF | $17.112 -17.59% 1.5K
|
Health Technology
|
| O: -1.42%
H: 0.02%
C: 0.02%
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -3.62%
H: 0.0%
C: -0.56%
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: -1.44%
H: 5.82%
C: 1.91%
TRUMY | $16.69 0.79% 54K
|
Manufacturing
|
| O: -1.37%
H: 0.68%
C: 0.37%
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: -1.8%
H: 0.08%
C: -0.43%
MDT | $79.19 0.14% 0.0% 6.1M
|
Health Technology
|
| O: -0.2%
H: 0.66%
C: -0.52%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 1.9%
H: 0.0%
C: 0.0%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.82%
H: 0.92%
C: 0.66%
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: 2.71%
H: 2.77%
C: 1.21%
BDX | $233.15 0.41% 0.15% 890K
|
Health Technology
|
| O: -0.3%
H: 0.1%
C: -1.63%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.51%
H: 0.0%
C: 0.0%
PODD | $164.71 -0.93% -0.94% 590K
|
Health Technology
|
| O: -0.82%
H: 0.38%
C: -2.71%
ENDP | $0.2926 -9.6%
|
Health Technology
|
| O: -5.76%
H: 7.53%
C: 0.47%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: 0.33%
H: 0.0%
C: 0.0%
ATRS | $5.59 0.0%
|
Health Technology
|
| O: -0.31%
H: 0.7%
C: -0.63%
drug liver growing drug delivery
Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021
Published: 2021-11-12 (Crawled : 14:00) - biospace.com/
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: 0.0%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: 0.0%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -2.06%
H: 0.0%
C: 0.0%
disease liver disease phase 1 liver trial
Home-Use Insulin Delivery Devices Market to Hit $19,087.6 Million Revenue by 2030 says P&S Intelligence
Published: 2021-08-18 (Crawled : 08:00) - prnewswire.com
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: 0.04%
H: 0.72%
C: -0.91%
MDT | $79.19 0.14% 0.0% 6.1M
|
Health Technology
|
| O: 0.03%
H: 0.28%
C: -1.12%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.26%
H: 1.01%
C: -1.28%
BDX | $233.15 0.41% 0.15% 890K
|
Health Technology
|
| O: 0.07%
H: 0.3%
C: -2.11%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.17%
H: 1.16%
C: -0.04%
PODD | $164.71 -0.93% -0.94% 590K
|
Health Technology
|
| O: 0.21%
H: 0.12%
C: -2.14%
insulin device liver
Dicerna Announces Interim Results From Phase 1 Trial of Belcesiran for Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Published: 2021-07-21 (Crawled : 13:00) - biospace.com/
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: 0.9%
H: 0.72%
C: 0.58%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.58%
H: 0.42%
C: 0.38%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 0.45%
H: 0.0%
C: -2.13%
disease liver disease treatment phase 1 results liver trial phase 2 phase 3
Dicerna Initiates Patient Dosing in ESTRELLA Phase 2 Clinical Trial of Belcesiran for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Published: 2021-06-22 (Crawled : 12:15) - biospace.com/
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: -0.39%
H: 0.27%
C: -0.21%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.02%
H: 0.44%
C: -0.53%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 0.08%
H: 1.01%
C: 0.9%
disease liver disease treatment phase 2 liver trial
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.